Juangoz
Member
id like your takes on this topic but here is mine: infigratib is more selective for FGFR1-3 and less FGFR4 activity, in theory which means it could lead to more targeted growth plate activity and less sides, whislt erdafitinib is pan a FGFR1-4 inhbitor meaning a stronger FGFR4 hit. In theory Erdafitinib would be stronger for height but there is real risks with it. Also in my case for Erdafitinib there is real clinical evidence, doctors report rapid overgrowth in teens who take it and in one case a teen reached a state of 19cm a year growth also all these pacients are normal non androcrolopasia unlike the studies for Infigratinib
